title: Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
abstract: Ten patients with previously untreated stage III/IV low grade histology non-Hodgkin's lymphoma received a 1-hour intravenous infusion of Didemnin B 2.3 mg/m2 weekly for 4 weeks repeated every 6 weeks. 40% of patients experienced significant hypersensitivity reactions, one of which was life-threatening, despite premedication with diphenhydramine and cimetidine. Other toxicities included nausea, vomiting, fatigue, diarrhea and skin rashes. No objective responses were seen. Given the serious toxicity and lack of activity in a non-pretreated group of patients, the study was closed early. Further investigation of Didemnin B at this dose and schedule is not recommended.
authors.affiliation: Ottawa General Hospital, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Goss
authors.forename: A
authors.initials: A
authors.lastname: Muldal
authors.forename: R
authors.initials: R
authors.lastname: Lohmann
authors.forename: M
authors.initials: M
authors.lastname: Taylor
authors.forename: P
authors.initials: P
authors.lastname: Lopez
authors.forename: G
authors.initials: G
authors.lastname: Armitage
authors.forename: W P
authors.initials: WP
authors.lastname: Steward
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047630:Depsipeptides; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; C030051:didemnins